Continuous PSMA-PET metrics sharpen prognosis in metastatic castration-resistant prostate cancer

Continuous PSMA-PET metrics (e.g., SUVmax, tumor volume) improved prognostication for patients with mCRPC compared with binary positive/negative reads, reports RSNA News. (Exact effect sizes not provided in source.)

• The news item summarizes a study demonstrating that quantifying PSMA-PET avidity on a continuum rather than a simple positive/negative classification better stratifies patient outcomes; exact design and n not detailed in the source.
• No secondary numerical finding or external validation mentioned in the snippet.
• Lacking full study details, the generalizability and prospective validation of these continuous metrics remain unclear from this summary.

RadPigeon summaries are original and for information only. They are not clinical advice.